ZEB2

Across TCGA pan-cancer cohorts, ZEB2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZEB2 data layer compared with 27 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZEB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZEB2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ZEB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.965	0.760	.004	23	view →
LUAD	DFS	Tertile	All	0.770	0.373	.002	12	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.470	.006	9	view →
LSCC	DFS	Median	All	0.845	0.734	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZEB2–PDAC (OS)

Open the PDAC breakdown →